Bryn Williams-Jones

#SynbiTECH2024 concludes with a fireside chat between Paul Freemont and Richard Kitney, hosted by Fiona Mischel of SynBioBeta. "Synbio Unplugged: Twenty years of evolution" considers two decades of development of the field. The discussion also looks forward to the next decade of advances. The establishment of data-driven tools and experimental pathways to develop the genetic and cellular tools will enable the commercial application at scale. Paul points to the need for many early stage companies to engage with scale-up, and particularly to couple their upstream process to cost-effective and efficient downstream processes. This is often a neglected area. Dick points out the need to provide continuity of funding commensurate with effort and timelines needed to develop a national infrastructure to deliver the potential. The panel agrees that excellent science is not being translated in the UK. Paul says that companies are being made and grown, but then they are exported. Dick and Paul agree that this could be the UK's strength. The question is why large industry isn't stepping up to drive technology at the largest scale. Paul applauds the ambition, but rightly poses the question of how we can make that happen. Dick and Paul point to the amount of young people in the room, and the enthusiasm and drive they bring to the Engineering Biology sector. SynbiTECH 2024 draws to a close, looking forward to SynbiTECH 2025. What a great and inspiring event. Well done to SynbiCITE and all of the organisers and staff involved in making it a huge success.

16

Glucose transporter 1 (GLUT1) overexpression has been in the news by Crystal Mackall (https://lnkd.in/eFFb74Wp) and Michel Sadelain (https://lnkd.in/eZ4fN9ya). This has shown to increase #potency and #persistence by altering the cells metabolic pathways. Did you know that a simple method to increase GLUT1 expression for #cellandgenetherapy is altering the cell culture environment (mimicking #TME)? It also increases their persistent tumor killing capacity (https://lnkd.in/esAiqeV4). xcellbio bioreactor and Cytek Biosciences spectral FC analysis.

56

3 Comments

Good morning everyone! Do you like AI and graph neural networks? (see what i did there? :-) ) Our blog today helps you discover how SpatialGlue, a groundbreaking model published in Nature Methods, leverages graph neural networks and dual-attention mechanisms to integrate spatial and multi-omics data, providing unprecedented insights into tissue architecture and cellular interactions. Read our blog for a summary of how this innovative approach outperforms traditional models, offering precise mapping of complex structures and advancing research in fields like cancer and neurology. #SpatialTranscriptomics #ComputationalBiology #Bioinformatics #AI

12

 🧬 𝙏𝙝𝙚 𝙞𝙢𝙥𝙖𝙘𝙩 𝙤𝙛 𝙂𝙚𝙣𝙤𝙢𝙞𝙘𝙨 𝙤𝙣 𝘾𝙝𝙞𝙡𝙙 𝘾𝙖𝙣𝙘𝙚𝙧 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨 🧬 The integration of whole genome sequencing (WGS) in Pediatric cancer care is revolutionising how we diagnose and treat these challenging conditions. The potential of making WGS accessible to the wider demographic is huge, how can we accelerate this? 💡A recent article highlights the transformative potential of WGS in understanding the genetic makeup of cancers, paving the way for more personalised and effective treatments. https://lnkd.in/eD9W2qHz Sources: Sky News University of Cambridge BMJ #Genomics #CancerResearch #PediatricOncology #PrecisionMedicine #HealthcareInnovation

22

The capabilities of our Bioinformatics, Biostatistics and Software Development team complement our wet lab operations in every aspect of supporting biomarker programmes, as well as providing stand-alone technical services for clients who might need Data Science support. Find out more: https://hubs.li/Q02SvJ2s0 #DataScience #Bioinformatics #Biostatistics #SoftwareDevelopment #Biomarkers #Diagnostics

13

It’s been a great 2024 for Cancer Research Horizons, with plenty of activity to post about on Linkedin over the course of year. Particular stand outs include; the first patient dosing of several novel portfolio drugs in pancreatic, oesophageal, breast, blood and solid tumour studies; our portfolio companies raising over $300m of new capital to invest in areas such as ADCs, TME & molecular glues; seed financing newcos in areas including brain cancer, RNA, virtual reality and chemotherapy induced sepsis; and launching our new £28m global C:further initiative with LifeArc to discover new drugs addressing childhood cancers. Exciting stuff but still plenty more on the horizon for next year. Have a lovely festive break all. #OnMyHorizon #ChildhoodCancer #CancerResearch

92

2 Comments

Testing out new Chat GPT 4.0... It's remarkably good at summarising and producing structured answers. Hey Chap GTP, What impact do you think iPSCs will have on ALS drug discovery? ChatGPT Induced pluripotent stem cells (iPSCs) are expected to significantly impact amyotrophic lateral sclerosis (ALS) drug discovery in several key ways: Disease Modeling: iPSCs can be generated from patients with ALS and differentiated into motor neurons, the cell type primarily affected by the disease. This allows researchers to create patient-specific models of ALS in the lab. These models are invaluable for studying disease mechanisms and for screening potential drug candidates in a context that closely mimics human pathology. Personalized Medicine: Because iPSCs can be derived from individual patients, they facilitate the study of genetic variability in ALS. Researchers can explore how different genetic mutations contribute to the disease and how patients with different genetic backgrounds respond to treatments. This paves the way for personalized medicine approaches, where treatments can be tailored to the genetic profile of individual patients. High-Throughput Drug Screening: iPSC-derived neurons can be used in high-throughput screening to test thousands of compounds for potential therapeutic effects. This approach can rapidly identify promising drug candidates that can then be further validated in more complex models and eventually in clinical trials. Understanding Disease Mechanisms: iPSCs provide a platform for investigating the cellular and molecular mechanisms underlying ALS. By differentiating iPSCs into various neural cell types, scientists can study the interactions between motor neurons, astrocytes, and other cell types involved in ALS pathology. This comprehensive understanding is crucial for identifying new therapeutic targets. Testing Drug Toxicity and Efficacy: iPSC-derived motor neurons can be used to test the toxicity and efficacy of drug candidates before they enter clinical trials. This helps ensure that only the most promising and safest drugs move forward in the drug development pipeline, potentially reducing the time and cost associated with bringing new therapies to market. In summary, iPSCs offer a versatile and powerful tool for ALS drug discovery. They enable the creation of disease models that closely replicate human pathology, facilitate personalized medicine, support high-throughput drug screening, improve our understanding of disease mechanisms, and offer new avenues for testing drug safety and efficacy. These advantages collectively accelerate the pace of discovery and increase the likelihood of finding effective treatments for ALS. #ipscs #chatgpt

30

2 Comments

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

2

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

2

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

3

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

3

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1